Guggenheim 3rd Annual Healthcare Innovation Conference - AXSOME THERAPEUTICS INC

Financial Performance:

• Q3 revenue reached $260 million, surpassing an annualized run rate of $1 billion for the first time.
• Avelity generated $208 million in revenue, reflecting 53% year-over-year growth (accelerated from 51% in Q2) and 15% sequential growth.
• Senose (Xyrem for excessive daytime sleepiness) contributed $46 million, boosted by an $8.5 million milestone payment.
• Sembravo reported $3.9 million in revenue, showing strong sequential growth.
• Net loss narrowed to $13 million; the company achieved its first quarter of positive cash flow, generating $5–6 million in adjusted cash flow excluding $28 million in stock-based compensation.
• Cash balance stands at $314 million.
• Gross-to-Net (GTN) ratios improved in Q3, with the mid-to-high 40s range, driven by maximum covered lives and favorable payer mixes.

Guidance and Future Outlook:

• 2027 is anticipated as a significant year for milestone catalysts and potential commercial expansion.
• Avelity is expected to see continued robust growth, with accelerated momentum in the Alzheimer's disease agitation (ADA) indication.
• GTN guidance for Q4 suggests a potential slight increase; 2027 outlook is projected to mirror 2026 quarterly trends, pending Medicare mix changes and coverage quality improvements.
• Avelity MDD and ADA growth are supported by a 50%+ increase in New Rx (NBRx) velocity over the last two quarters.
• Long-term runway extends to 2038/2039 with potential pediatric indications.

Business Segments and Product Lines:

• Avelity: Leading commercial product with two indications (MDD and ADA); field force expanded from ~270 to ~650 representatives in six months to support the new ADA launch and MDD growth.
• Senose: Growing steadily in its approved indication (EDS) with low single-digit sequential growth despite a fixed sales team investment; peak sales potential estimated at $300–$500 million.
• Sembravo: Acute migraine treatment; receiving strong clinician and patient feedback with volume growth, though navigating complex commercial dynamics.
• Pipeline: 10 programs, heavily weighted toward NDA or Phase 3 stages; key milestones include AXS-12 (dextromethorphan/ropivacaine) for cataplexy/narcolepsy (PDUFA May 1), binge eating disorder readout (Q1 2025), and Synose expansion trials (ADHD, MDD, shift work disorder).

Market and Competitive Landscape:

• Avelity maintains strong payer access: 89% of covered lives for MDD and 100% for Medicare patients (vast majority with no prior authorization or step therapy).
• Primary care penetration is currently around 25% but is expected to grow significantly.
• Long-term care (LTC) channel is active with dedicated sales teams, expected to drive future prescribing as facility activation processes mature.
• AXS-12 enters the narcolepsy market distinct from orexin agonists, targeting specific patient profiles with a different tolerability and efficacy profile; marketed as an orphan drug with existing sleep infrastructure.
• Competition in psychiatry involves rising placebo response rates, necessitating robust study designs (e.g., randomized withdrawal trials).

Risks and Challenges:

• Commercial execution risks regarding field force optimization and the translation of new prescription (NBRx) velocity into refill revenue (TRX) typically takes a couple of quarters.
• Payer dynamics and potential pressure on Gross-to-Net ratios if coverage quality (e.g., moving to "preferred" status) is not maintained or improved.
• Regulatory timelines and trial outcomes for pipeline assets, particularly the requirement for two adequate and well-controlled trials for the binge eating disorder indication despite prior approval for related conditions.
• Rising placebo response rates in psychiatric trials may impact efficacy signal detection in upcoming studies.

Management Commentary and Tone:

• Management expressed high confidence, stating "things have never been better" regarding the business trajectory.
• Emphasis on the strategic decision to double the sales force rapidly to capitalize on new indications and payer access before the market matures.
• Tone is optimistic regarding the 2027 catalyst calendar and the transition to sustained cash flow positivity.
• Leadership highlighted the "funnel" effect of sales rep productivity leading to future refill revenue.

Analyst Questions and Answers:

• ADA Growth: Management confirmed NBRx growth for the ADA indication grew 3.6x (1,000 to 3,600 monthly) post-approval; TRX is expected to catch up in coming quarters.
• Sales Force ROI: The expanded team of 650 reps is now delivering ROI, with new reps averaging 4–6 months on the job.
• MDD vs. ADA Drivers: Growth is driven by both MDD continuity and accelerated ADA new business; primary care expansion is a key lever.
• Binge Eating Trial: A positive top-line result in Q1 2025 defines a "win," followed by a second confirmatory trial before NDA submission.
• AXS-12 Review: The review process is tracking as expected with 50% of the cycle complete; market differentiation from orexin drugs is the primary strategic focus.
• Cash Flow: Management confirmed Q3 was cash flow positive and indicated a focus on sustained profitability while reinvesting in top-line growth.

Other Key Points:

• The company's balance sheet strength ($314M cash) allowed for aggressive sales force expansion without compromising financial health.
• The company is actively navigating the "activation" phase in Long-Term Care facilities, which involves complex decision-making processes but offers high stickiness once established.
• Synose's growth in the current indication is achieved with a static sales team and marketing spend, demonstrating operational efficiency.
• The company does not provide specific quarterly revenue guidance but provides qualitative guidance on continued momentum.